GCG and myocardial infarction: In the SUSTAIN-6 study, semaglutide, another GLP-1 analog, was associated with a significantly lower risk of the primary composite outcome of death from cardiovascular causes, non-fatal myocardial infarctions, or non-fatal strokes than did those receiving a placebo (Marso et al., 2016b).